PLx Pharma GAAP EPS of -$0.30, revenue of $0.39M

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets
PLx Pharma Inc. Receives Nasdaq Delisting Notice
PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update
PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update
Baseball Legend John Smoltz Featured on PLx Pharma's Social Channels
Survey: Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE® 81 mg
PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update
PLx Pharma Inc. to Report Second Quarter 2022 Financial Results August 12, 2022, and Provide Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.